CYTOSORBENTS CORPORATION |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.868 USD | +3.21% |
|
+6.17% | -22.52% |
| May. 09 | Earnings Flash (CTSO) CYTOSORBENTS Posts Q1 Revenue $9.8M, vs. Street Est of $9.79M | MT |
| May. 09 | Transcript : Cytosorbents Corporation, Q1 2024 Earnings Call, May 09, 2024 |
Presenter SpeechStefan Baudis (Executives)Yes, hello, everybody, and a warm welcome here from ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in intensive care (ICU) and cardiac surgery using blood purification via its proprietary polymer adsorption technology. The Companyâs flagship product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy, and pancreatitis. Its other products include CytoSorb, animal-targeted VetResQ, DrugSorb-ATR and ECOS-300CY. Its other product candidates under development, including CytoSorb XL, BetaSorb, ContrastSorb, DrugSorb, HemoDefend-RBC, HemoDefend-BGA, K+ontrol, and others consist of a cartridge containing adsorbent, porous polymer beads, although the polymers used in these devices are physically different.
Calendar
2024-06-06
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.841
USD
Average target price
2.667
USD
Spread / Average Target
+217.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.52% | 45.67M | |
| +12.81% | 229B | |
| +14.60% | 195B | |
| +17.92% | 142B | |
| +28.94% | 109B | |
| +3.27% | 64.85B | |
| +18.32% | 54.33B | |
| +7.63% | 52.09B | |
| +10.84% | 45.15B | |
| +5.73% | 37.39B |
- Stock Market
- Equities
- CTSO Stock
- News Cytosorbents Corporation
- Transcript : Cytosorbents Corporation - Special Call